Moradi Mahmoudreza, Derakhshandeh Katayoun, Karimian Babak, Fasihi Mahtab
Department of Urology, Imam Reza Hospital, Kermanshah University of Medical Sciences, Kermanshah, Iran. Email:
J Inj Violence Res. 2016 Jul;8(2):75-9. doi: 10.5249/jivr.v8i2.812. Epub 2016 Apr 19.
Evaluation of the safety and efficacy of intraurethral Mitomycin C (MMC) hydrogel for prevention of post-traumatic anterior urethral stricture recurrence after internal urethrotomy.
A thermoresponsive hydrogel base consisting of 0.8 mg MMC with 1cc water and propylene glycol to PF-127 poloxamer was used in theater. 40 male patients with short, non-obliterated, urethral stricture were randomized into 2 groups: control and MMC. After internal urethrotomy, the MMC group patients received the MMC-Hydrogel while the others were just catheterized. Both groups had their catheters for at least 1 week. After surgery, they were followed up by means of medical history and physical examination, monitoring voiding patterns and retrograde urethrogram at 1 month, 6 months and 1 year after surgery.
40 male patients between 14 to 89 years old (Mean = 54.15) underwent internal urethrotomy. The average age for the control and MMC group was 54.55±21.25 and 53.75±24.75 respectively. In a comparison of age between the two groups, they were matched (P=0.574). Stricture length was 10.7±5.9 and 9.55±4.15 mm for the control and MMC group respectively. There were no statistically meaningful differences between the two groups (P=0.485). Fifteen patients had a history of one previous internal urethrotomy which in a comparison between the two groups meant there was no meaningful difference (P=0.327). During postoperative follow up, total urethral stricture recurrence happened in 12 patients: 10 patients (50%) in control group and 2 patients (10%) in MMC group. The difference was statistically significant (P=0.001). There were no significant complications associated with the MMC injection in our patients.
Based on our results, MMC Hydrogel may have an anti-fibrotic action preventing post-traumatic anterior urethral stricture recurrence with no side effects on pre-urethral tissue. Due to our study limitations, our follow up time and the small number of patients, our results were not conclusive and further studies will be needed with a longer follow up time.
评估尿道内注射丝裂霉素C(MMC)水凝胶预防尿道内切开术后创伤性前尿道狭窄复发的安全性和有效性。
术中使用由0.8毫克MMC与1毫升水以及丙二醇和PF - 127泊洛沙姆组成的热响应性水凝胶基质。40例患有短段、非闭锁性尿道狭窄的男性患者被随机分为两组:对照组和MMC组。尿道内切开术后,MMC组患者接受MMC水凝胶治疗,而其他患者仅进行导尿。两组患者均留置导尿管至少1周。术后,通过病史和体格检查、监测排尿模式以及在术后1个月、6个月和1年进行逆行尿道造影对患者进行随访。
40例年龄在14至89岁(平均 = 54.15岁)的男性患者接受了尿道内切开术。对照组和MMC组的平均年龄分别为54.55±21.25岁和53.75±24.75岁。两组年龄比较,差异无统计学意义(P = 0.574)。对照组和MMC组的狭窄长度分别为10.7±5.9毫米和9.55±4.15毫米。两组之间无统计学意义上的差异(P = 0.485)。15例患者有过一次尿道内切开术史,两组比较差异无统计学意义(P = 0.327)。术后随访期间,共有12例患者发生尿道狭窄复发:对照组10例(50%),MMC组2例(10%)。差异具有统计学意义(P = 0.001)。在我们的患者中,MMC注射未引发明显并发症。
基于我们的研究结果,MMC水凝胶可能具有抗纤维化作用,可预防创伤性前尿道狭窄复发,且对尿道前组织无副作用。由于本研究存在局限性,随访时间较短且患者数量较少,我们的结果尚无定论,需要进行更长随访时间的进一步研究。